Eli Lilly and Co. LLY is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.Expectations are slightly higher for the quarter, primarily driven by the strong performance of its obesity drug, Zepbound. The pharmaceutical giant, a dominant player in the incretin/GLP-1 drug market for obesity and diabetes, continues to draw investor attention with its robust pipeline and long-term growt ...

If you spend much time perusing the stocks that Wall Street analysts expect to produce eye-popping returns, you may have noticed a common theme: There's usually a ton of risk involved. If you'd prefer a portfolio that can outperform the overall market without taking huge risks on each individual stock, sticking with dividend payers is the way forward. During the 50-year period that ended 2024, the average dividend-paying stock in the S&P 500 index delivered a 9.2% annualized return. Over the same time frame ...

Core Viewpoint - Hims & Hers Health, Inc. is facing significant challenges, including an 18% decline in stock price over the past month, primarily due to the termination of its collaboration with Novo Nordisk and ongoing legal scrutiny regarding its compounded drug offerings [1][2][3]. Company Developments - The termination of the collaboration with Novo Nordisk in June 2025 has resulted in Hims & Hers losing direct access to Wegovy, a popular GLP-1 weight-loss drug [1][3]. - Hims & Hers aims to achieve $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030, despite current challenges [3]. - The company reported over $225 million in revenue from GLP-1 products in 2024, indicating some success in this segment [6]. Regulatory and Legal Context - Novo Nordisk cited Hims & Hers' alleged failure to comply with laws regarding compounded drugs and deceptive marketing practices as reasons for ending the collaboration [2]. - The FDA's removal of semaglutide from the drug shortage list has impacted Hims & Hers, as it indicates sufficient supply to meet demand, reducing the justification for compounded versions [5]. - Legal scrutiny is focused on the legality of mass-producing compounded versions of GLP-1 drugs now that the official shortage is over [6][7]. Market Implications - Analysts from Morgan Stanley have noted an increased focus on the legal and business implications for Hims & Hers, particularly in light of Eli Lilly's lawsuits against compounding pharmacies [7][12]. - Experts suggest that compounding pharmacies should cease large-scale production of GLP-1 drugs once the shortage ends, although there may be cases for compounding under specific regulations [8][9]. - The ongoing legal cases could take 2 to 3 years to resolve, impacting the operational landscape for Hims & Hers [12]. Strategic Moves - Hims & Hers announced an agreement to acquire ZAVA, a digital health platform in Europe, which will expand its presence in the UK and enter new markets such as Germany, France, and Ireland [13].

Investment Rating - The report indicates a favorable outlook for both Zepbound and Wegovy, with physicians rating Zepbound higher in efficacy, tolerability, and patient satisfaction compared to Wegovy [7][36]. Core Insights - Zepbound is expected to continue gaining market share from Wegovy, with a projected 60:40 split in favor of Zepbound within a year [7]. - The removal of compounded GLP-1s is anticipated to benefit both Novo and Lilly, with nearly 75% of patients expected to switch to branded products [7]. - Physicians expect Zepbound and Wegovy to retain approximately 50% of the market share in five years, with oral GLP-1s and next-gen high-efficacy products capturing the remaining share [7]. - Reimbursement remains a significant hurdle, with around 40% of patients denied coverage for GLP-1s, primarily due to lack of insurance coverage and insufficient comorbidities [9][40]. Summary by Sections Key Obesity Survey Takeaways - Zepbound has overtaken Wegovy in prescriptions, with current shares at 42% for Zepbound and 40% for Wegovy [28]. - Physicians expect a 60:40 split in favor of Zepbound in the next year as compounded GLP-1s exit the market [28]. - Cost is the primary reason for treatment discontinuation, affecting both Zepbound and Wegovy similarly [62]. Key Novo Takeaways - Novo is expected to benefit from the reduced availability of compounded products, with Wegovy gaining around 50% of patients switching from compounded drugs [11]. - The launch of oral Wegovy and other high-efficacy products is crucial for Novo to maintain market share [11]. - Efforts to improve reimbursement processes are expected to unlock significant market growth for both Novo and Lilly [11]. Key Eli Lilly Takeaways - Zepbound's market share is projected to grow from approximately $12.5 billion in 2025 to nearly $20 billion by 2027 [13]. - The pipeline for Lilly's incretin franchise is expected to expand significantly, with oral GLP-1s anticipated to capture around 20% market share in five years [13]. - LillyDirect and other direct-to-consumer channels are becoming increasingly important for Zepbound's market penetration [13]. Reimbursement Insights - The survey indicates that 40% of patients prescribed GLP-1s are denied reimbursement, with the most common reasons being lack of insurance coverage and insufficient comorbidities [40]. - Approximately 60% of patients denied coverage opt for out-of-pocket treatments [41]. - As insurance coverage improves, the fill rate for GLP-1 prescriptions is expected to increase, benefiting both Novo and Lilly [44]. Market Share Expectations - In five years, Zepbound is expected to maintain a leading share of around 30%, with Wegovy and oral GLP-1s each capturing approximately 20% [48]. - Physicians anticipate that the use of weight loss medications among heavier patients (BMI ≥40) will increase significantly if higher efficacy options become available [51].

Core Viewpoint - Novo Nordisk's weight loss and diabetes drugs, Wegovy and Ozempic, are linked to rare but serious eye conditions, prompting regulatory scrutiny and potential label updates [2][3][8]. Group 1: Regulatory Actions and Findings - The European Medicines Agency's safety committee confirmed a link between semaglutide (active ingredient in Wegovy and Ozempic) and non-arteritic anterior ischemic optic neuropathy (NAION), a serious eye condition [2][3]. - Novo Nordisk has been asked to include NAION as a "very rare" side effect in the product information for semaglutide-containing drugs [3]. - The committee noted that the risk of developing NAION is doubled for diabetes patients using semaglutide compared to those not taking it [5]. Group 2: Patient Impact and Risk Assessment - The incidence of NAION may affect up to 1 in 10,000 patients taking semaglutide for at least one year, indicating that it is likely not a significant concern for the majority of users [5]. - The eye condition is the second-most common cause of blindness due to optic nerve damage, primarily affecting individuals aged 50 and above [6]. Group 3: Additional Research and Concerns - A recent study indicated that diabetes patients using GLP-1 drugs like Ozempic are twice as likely to develop neovascular age-related macular degeneration (nAMD) compared to non-users [8][9]. - The study analyzed health records of nearly 140,000 adults with Type 2 diabetes, primarily focusing on the effects of semaglutide [10]. - Novo Nordisk maintains that the efficacy and safety of semaglutide have been well-established, despite these emerging concerns [10].

Weight-loss drugs are suppressing appetites for millions of Americans, threatening to upend dining habits at fast-food chains and casting a shadow over the restaurant industry’s long-term growth.The stark warning came from Redburn Atlantic, which on Tuesday issued a rare double downgrade on McDonald's Corp. MCD — cutting the stock from Buy to Sell — amid growing concern that appetite-suppressing medications such as Novo Nordisk A/S’s NVO Wegovy and Eli Lilly and Co.’s LLY Zepbound are reshaping consumer beh ...

Core Viewpoint - Eli Lilly is set to present new data on multiple GLP-1 drugs at the American Diabetes Association (ADA) event, which could significantly impact its stock performance and growth prospects [4][5][10] Group 1: Upcoming Events - The ADA's 85th Scientific Sessions will take place from June 20 to 23, where Eli Lilly will report on studies related to GLP-1 drugs, including tirzepatide, orforglipron, and retatrutide [4] - An investor event hosted by Eli Lilly on June 22 will discuss key presentations from the ADA Scientific Sessions [4] Group 2: Stock Performance and Market Sentiment - Eli Lilly's stock has been flat since the start of 2025, with no significant catalysts to drive its price higher, despite reaching over $900 earlier this year [6] - The stock is currently trading at more than 60 times its trailing earnings, indicating that investors expect near-perfect performance from the company [7] Group 3: Financial Performance - Over the trailing 12 months, Eli Lilly generated revenue exceeding $49 billion, with profits totaling $11.1 billion, a significant increase from less than $29 billion in revenue and $6.2 billion in profit in 2022 [8] - The growth attributed to new GLP-1 drugs has positively transformed the company's financial outlook [8] Group 4: Investment Potential - Eli Lilly is viewed as a strong business with promising growth prospects, potentially reaching a $1 trillion valuation in the coming years, representing an upside of over 45% from its current position [9] - Despite unimpressive year-to-date returns, the stock is considered to have significant room for growth, making it an attractive investment opportunity ahead of the ADA event [10]

Core Viewpoint - The departure of CEO Lars Fruergaard Jørgensen from Novo Nordisk A/S comes amid significant challenges in the weight loss and diabetes drug market, particularly due to increased competition from Eli Lilly and Company, which has led to a decline in Novo's market share and stock performance [1][3][11]. Group 1: CEO Departure and Company Performance - Jørgensen has been CEO since January 2017, during which Novo Nordisk achieved a total return of approximately 304%, significantly outperforming the S&P 500's 199% return [2]. - However, in the past 52 weeks, Novo's stock has declined nearly 52% from its peak on June 25, 2024, indicating recent struggles [2]. - The company's market share in the weight loss drug sector has fallen from approximately 71% to around 55% as of Q1 2025, primarily due to the rapid growth of Eli Lilly's Zepbound [4]. Group 2: Competitive Landscape - Eli Lilly's tirzepatide has shown to achieve about 47% more weight loss compared to Novo's semaglutide, contributing to Novo's loss of market share [3]. - Recent trial results for Novo's experimental drug CagriSema showed an average weight loss of 22.7%, which was below expectations and only slightly higher than tirzepatide's 22.5% [5][6]. - Following disappointing trial results, Novo's shares dropped significantly, with an 18% decline after the CagriSema announcement and over 9% after further disappointing results [6][7]. Group 3: Future Leadership and Strategy - Analysts suggest that Novo's next CEO may be an external hire, potentially an American, to better navigate the U.S. market, which accounted for 57% of Novo's sales last quarter [8][9]. - The new CEO will need to revitalize Novo's drug pipeline to compete effectively with Eli Lilly, with hopes pinned on the potential of UBT251, a "triple-agonist" drug [10]. - The upcoming earnings report on August 6 is anticipated to provide further insights into Novo's strategic plans and stock outlook [11].

Veru ( NASDAQ: VERU ) is a late-clinical-stage biopharma company emerging from a comprehensive restructuring effort in 2024. After divesting its commercial sexual health business for $18 million in 2024, Veru has pivoted toward an entirely new Analyst's Disclosure: I/we have a beneficial long position in the shares of VERU either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeki ...

Group 1: Eli Lilly - Eli Lilly is identified as a top growth stock in the healthcare sector, driven by its GLP-1 offerings, Zepbound and Wegovy, which are in early growth stages [3] - The company's revenue surged from less than $29 billion in 2022 to over $45 billion in 2023, marking a 58% growth in two years [4] - Zepbound generated $4.9 billion in revenue last year, while Mounjaro's sales more than doubled to $11.5 billion, making it the top-selling drug for Eli Lilly [5] - Eli Lilly is focusing on the lucrative GLP-1 drug market and is working on a weight loss pill, orforglipron, which may receive approval next year [6] - Despite a high valuation of $800 billion and trading at over 75 times trailing earnings, Eli Lilly is projected to reach a $1 trillion valuation within the next one to two years [7] Group 2: Novo Nordisk - Novo Nordisk remains a leader in diabetes and obesity care, despite recent clinical setbacks affecting its pipeline [9] - The company's stock has dropped nearly 50% over the past year, making it more attractively priced for investors [9][11] - Novo Nordisk is expanding its product development beyond endocrine-related disorders, which is strategic given the competition in the weight management market [10] - The company has a deep pipeline with investigational drugs targeting various areas, indicating strong long-term prospects [11] Group 3: Vertex Pharmaceuticals - Vertex Pharmaceuticals has seen a 24% increase in stock price year-to-date, indicating strong market performance [12] - The approval of its new pain medication, Journavx, is expected to drive significant commercial potential and momentum [13] - Vertex has launched Alyftrek, a cystic fibrosis therapy that offers more convenient dosing and is expected to be more profitable [14] - The company is optimistic about its gene-editing therapy, Casgevy, which has multibillion-dollar potential despite slow initial uptake [15] - Vertex has four programs in phase 3 testing, including zimislecel, which could potentially cure severe type 1 diabetes [16]